PE20210458A1 - DAILY HYDROSMINE FORMULATION - Google Patents

DAILY HYDROSMINE FORMULATION

Info

Publication number
PE20210458A1
PE20210458A1 PE2020000781A PE2020000781A PE20210458A1 PE 20210458 A1 PE20210458 A1 PE 20210458A1 PE 2020000781 A PE2020000781 A PE 2020000781A PE 2020000781 A PE2020000781 A PE 2020000781A PE 20210458 A1 PE20210458 A1 PE 20210458A1
Authority
PE
Peru
Prior art keywords
hydrosmine
formulation
daily
hemorrhoids
edema
Prior art date
Application number
PE2020000781A
Other languages
Spanish (es)
Inventor
Herrero Gonzalo Hernandez
Azpitarte Ignacio Ortega
Garcia Tania Gonzalez
Urlanga Lorena Gonzalez
Esperanza Beascoa-Alzola
Bullon Alejandro Vicente
De Campo Nuria Montes
Negre Jose Maria Sune
Pujol Francisco Gual
Carreras Manuel Roig
Ricart Anna Nardi
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of PE20210458A1 publication Critical patent/PE20210458A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a una formulacion que comprende hidrosmina caracterizada por una velocidad de liberacion modificada adecuada para la administracion una vez al dia. Tambien se proporciona el uso de dicha composicion en la prevencion o el tratamiento de una enfermedad seleccionada de insuficiencia venosa cronica, varices, hemorroides, edema, sindrome metabolico, esteatosis hepatica no alcoholica y nefropatia diabetica.The present invention relates to a formulation comprising hydrosmine characterized by a modified release rate suitable for once daily administration. Also provided is the use of said composition in the prevention or treatment of a selected disease of chronic venous insufficiency, varicose veins, hemorrhoids, edema, metabolic syndrome, non-alcoholic hepatic steatosis and diabetic nephropathy.

PE2020000781A 2017-12-21 2018-12-20 DAILY HYDROSMINE FORMULATION PE20210458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382877 2017-12-21
PCT/EP2018/086053 WO2019122051A1 (en) 2017-12-21 2018-12-20 Once-daily formulation of hidrosmin

Publications (1)

Publication Number Publication Date
PE20210458A1 true PE20210458A1 (en) 2021-03-08

Family

ID=60923332

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000781A PE20210458A1 (en) 2017-12-21 2018-12-20 DAILY HYDROSMINE FORMULATION

Country Status (15)

Country Link
EP (1) EP3727345A1 (en)
AR (1) AR113993A1 (en)
BR (1) BR112020012437A2 (en)
CL (1) CL2020001697A1 (en)
CO (1) CO2020008721A2 (en)
CR (1) CR20200320A (en)
EA (1) EA202091535A1 (en)
EC (1) ECSP20041796A (en)
MX (1) MX2020006505A (en)
NI (1) NI202000049A (en)
PE (1) PE20210458A1 (en)
PH (1) PH12020550926A1 (en)
SG (1) SG11202005652YA (en)
UY (1) UY38026A (en)
WO (1) WO2019122051A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5894720B2 (en) 2010-05-11 2016-03-30 シマ ラブス インク． Alcohol resistant formulation
CN108366969A (en) 2015-10-09 2018-08-03 拜尔健康护理有限责任公司 The Modified Release Formulation of naproxen sodium

Also Published As

Publication number Publication date
UY38026A (en) 2019-07-31
SG11202005652YA (en) 2020-07-29
AR113993A1 (en) 2020-07-08
EP3727345A1 (en) 2020-10-28
NI202000049A (en) 2020-11-24
WO2019122051A1 (en) 2019-06-27
CL2020001697A1 (en) 2020-11-27
BR112020012437A2 (en) 2020-11-24
CO2020008721A2 (en) 2020-12-10
MX2020006505A (en) 2020-09-17
EA202091535A1 (en) 2020-09-11
PH12020550926A1 (en) 2021-05-31
CR20200320A (en) 2020-12-14
ECSP20041796A (en) 2020-10-30

Similar Documents

Publication Publication Date Title
ECSP19021223A (en) DERIVATIVE OF GLUCAGON, CONJUGATE OF THE SAME, COMPOSITION INCLUDING THE SAME AND THERAPEUTIC USE OF THE SAME
PE20191474A1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CL2018002532A1 (en) Pharmaceutical composition comprising empagliflozin and its uses
CL2017002939A1 (en) Topical pharmaceutical compositions
CL2015003117A1 (en) Crystal structure modifications
ECSP11011278A (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES DERIVATIVES OF GLUCOPIRANOSIL DIFENYLMETHANE, PHARMACEUTICAL FORM OF THE SAME, PROCEDURE FOR THEIR PREPARATION AND USES OF THE SAME FOR IMPROVED GLUCEMIC CONTROL IN A PATIENT.
AR091089A1 (en) TREATMENT METHODS THAT USE A BIGUANIDA COMPOUND IN A DELAYED RELEASE FORMULATION
CL2019000575A1 (en) Amylin analogs.
PE20211069A1 (en) COMPOSITION INCLUDING 5'-METHYLSEELENOADENOSINE, SELENOADENOSYL-L-HOMOCYSTEIN AND GLUTAMYL-METHYLSELENOCYSTEINE RANGE
CL2016000008A1 (en) Treatment of inflammatory lesions of rosacea with ivermectin.
CL2016002276A1 (en) Topical compositions comprising an extract of coriolus versicolor to increase autoimmunity
CL2017001483A1 (en) Fixed ratio formulation of insulin glargine / lixisenatide
UY35651A (en) SUBSTITUTED PIRAZOLPIRIDINS
UY35848A (en) TIENOPIRIMIDINS
ES2517491T3 (en) Stabilizer of lymphatic vessels
PE20150721A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING GEMIGLIPTIN AND METFORMIN, AND METHOD FOR THEIR PREPARATION
AR102778A1 (en) PHARMACEUTICAL COMPOSITION, ITS PREPARATION AND ITS USES
UY37538A (en) AROMATIC AMIDES OF CARBOXYLIC ACIDS
PE20210458A1 (en) DAILY HYDROSMINE FORMULATION
CO2019011227A2 (en) Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
HN2011000661A (en) PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF SEXUAL TRANSMISSION INFECTIONS
ECSP16069947A (en) TOPICAL HEPARIN FORMULATIONS
CL2017003465A1 (en) Combined use of bumetanide with valproic acid or one of its pharmaceutically acceptable salts to restore cl-homeostasis and thereby allow the preparation of an effective drug in the treatment of epilepsy, and especially in the treatment of refractory epilepsy.
CO2019013940A2 (en) Methods to reduce or prevent cardiovascular events in patients with type ii diabetes mellitus
CO7170180A2 (en) Injectable pharmaceutical composition of dexketoprofen and tramadol